This paper examines the major legal and ethical frameworks that healthcare organizations must navigate to maintain integrity and prevent fraud. It covers qui tam whistleblower statutes and notable settlement cases involving major pharmaceutical and healthcare companies, Medicare and Medicaid admissions criteria including anti-kickback and self-referral regulations, the components of an effective corporate integrity program, and HIPAA-based patient information protection requirements. Together, these elements form a comprehensive picture of how healthcare organizations can structure compliance efforts to avoid substantial governmental penalties and uphold ethical standards.
The paper demonstrates effective use of enumerated evidence to build a cumulative argument. By listing multiple high-profile settlements chronologically, it shows a pattern of widespread non-compliance across major healthcare companies rather than treating fraud as an isolated incident. This strengthens the normative claim that proactive compliance programs are essential rather than optional.
The paper follows a problem-to-solution structure across six substantive sections. It opens by establishing the scope of healthcare fraud as both a legal and ethical problem, then details the qui tam legal framework and illustrative case law. It shifts to the regulatory environment (Medicare/Medicaid) before presenting two organizational responses: a corporate integrity program and HIPAA-based privacy protections. A brief conclusion ties these threads together. Each section is self-contained but contributes to a unified compliance framework.
Integrity is a major issue for healthcare organizations because there are many avenues for fraud and for people to demonstrate a lack of ethics. The problem is that the temptation is sometimes too great, and despite the laws in place to guard against these practices, unethical behavior occurs anyway. The government, which supplies a significant portion of the money that goes toward treatments through Medicare and Medicaid, has structured certain laws to ensure that the practices of healthcare organizations remain ethical — yet billions of dollars in fines are still levied every year. Large pharmaceutical companies complain of arcane and hard-to-decipher legal language, but the fact is that, although they recognize the issues and the penalties, they continue to subvert the law. This paper examines qui tam statutes and cases, Medicare and Medicaid admissions criteria, corporate integrity programs, and patient information protection law.
The phrase qui tam derives from Latin and relates specifically to an action taken on behalf of the government against a fraudulent individual or group. In the United States, these have been termed "whistleblower" statutes and refer to individuals who notice fraud conducted by their employer and report it to authorities. The laws that form part of this type of action protect the person who provides the information and, in most cases, allow them to do so anonymously. The statutes also provide for financial compensation for the individuals or groups who supply the information.
In the case of healthcare agencies or practices, this can take several forms. One study notes that "areas from patient referrals to billing and documentation have become targets for state and federal governments; investigation of healthcare fraud, false claims, and other types of noncompliance" (Mattie & Ben-Chitrit, 2009). Healthcare organizations may believe, through short-term thinking, that the fraud is not serious enough to warrant closer investigation, but the damages the government can demand are substantial and should serve as a major warning to any organization. The False Claims Act provides that "the government may recover up to three times the amount of damages it sustained as a result of the defendant's fraud plus $5,500–$11,000 per fraudulent claim" (Mattie & Ben-Chitrit, 2009). This should provide healthcare managers with sufficient motivation to remain within the law and conduct in-house investigations whenever any type of fraud that could fall under qui tam statutes is suspected.
Precedent has been established in these types of cases by the number brought before state and federal courts. In recent years, there has been a series of large lawsuit settlements that have benefited the government, whistleblowers, and the public alike. These include:
These cases are significant because the amounts required in settlement were very large. One of the companies listed above faced a fine of $3 billion, which demonstrates the seriousness with which the government pursues such claims.
Mattie, A., & Ben-Chitrit, R. (2009). The federal False Claims Act and qui tam actions: What every healthcare manager should know. Journal of Legal, Ethical and Regulatory Issues, 12(2), 49–65.
Yuspeh, A., Whalen, K., Cecelic, J., & Clifton, S. (1999). Above reproach: Developing a comprehensive ethics and compliance program / Commentaries / Reply. Frontiers of Health Services Management, 16(2), 3–21.
You’re 39% through this paper. Sign up to read the remaining 3 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.